SVG
Diversity in Clinical Trials
Diversity in Clinical Trials
Featured Thought Leadership
Hot Spots for Decentralized Clinical Trials: Reframing Old Challenges
Clinical research asks questions about how well an investigative treatment or diagnostic works, or how well and in what amounts existing treatments work by comparison. But, with a broader view, clinical research can do more. If research is...Read Article
Milken Institute Statement on Newly Released FDA Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Trials
The Milken Institute celebrates the publication of the second iteration of the Food and Drug Administration (FDA) draft guidance on Diversity Action Plans (DAP) to improve clinical trial diversity by enrolling underrepresented populations...Read StatementImage
Esther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report
June 24, 2024 (Washington, DC)— Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving treatments are often difficult or impossible...Read ArticleImage
Paul Guequierre
Director, Strategic CommunicationsPaul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
Toward a National Action Plan for Achieving Diversity in Clinical Trials
This report details the actions organizations and sectors from across the enterprise can take to create a clinical trials enterprise that is diverse, equitable, inclusive, and accessible to all.Read Report
BM
MH
SO
WD
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have been shown to skew disproportionately toward young, White, male participants. Variability also exists in a treatment’s effectiveness across...Read ReportAdvancing Clinical and Translational Science Through Accelerating the Decentralization of Clinical Trials
FasterCures, a center of the Milken Institute, is pleased to respond to your Request for Information on Advancing Clinical and Translational Science through Accelerating the Decentralization of Clinical Trials. FasterCures believes that it...Read LetterImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.End of Year Legislative Package – Health Provisions
I commend your leadership in passing legislation that advanced biomedical research this year, including reauthorizing the Food and Drug Administration’s (FDA) user fee programs.Read LetterImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Increasing Diversity in Clinical Trials to Reduce Health Disparities
In an incredibly diverse world, health inequities and resulting disparities continue to stand out as a persistent yet addressable challenge. As the global biopharmaceutical industry works to treat, prevent, or even cure diseases, we have a...Read Essay
Health Economics Driving New Investments
Panelists first explore the economic and financial toll of health inequities in hindering access to affordable health care, including drugs and treatments as well as participation in clinical trials. Conversely, they review measures that policymakers and industry—particularly within the C-suite—can take to effect meaningful change in making the health-care and research ecosystem more equitable and affordable.
Related Videos
Digital Health Equity and Technology: Where Are We Now?Research has shown that racial biases can be built into medical products, leading to misdiagnoses, inaccurate readings, and delays in therapy.
Building and Sustaining Diversity & Equity in Digital Health WorkshopDuring the workshop, experts discussed prevailing barriers to representation and inclusion and efforts to improve equity in digital health technologies.
Building a Diverse and Equitable Health Workforce to Increase Trust in Medical Research and HealthcareTo promote health equity within the biomedical research and health-care systems, we must focus on having a culturally competent and diverse workforce.
Improving Health Equity in Rare Diseases ResearchPeople with rare diseases face many barriers and inequities in accessing diagnosis, treatment, and comprehensive care. This burden is even greater among marginalized communities with rare diseases.
How Can We Ensure Access to Health Innovation for All?Innovation means nothing without access, and barriers to access for many patients—particularly for communities already underserved and lacking access to high-quality care—are real.
The New ROI: Advancing an Equitable and Inclusive Biomedical Research EcosystemAs a result of the COVID-19 pandemic, systemic health-care inequities persist along with public skepticism and mistrust in the system.
A Conversation with Marcella Nunez-Smith on COVID-19 and Health EquityA Conversation with Marcella Nunez-Smith on COVID-19 and Health Equity
The Impact of Investing in Health Equity in Biomedical ResearchBiomedical research relies on commercial investment, grant funding, and private donations to accelerate drug development, run clinical trials, and support innovation in health technologies.